Literature DB >> 27154179

Does Modern Management of Malignant Extracranial Disease Prolong Survival in Patients with ≥3 Brain Metastases?

Bengt Karlsson1, Masaaki Yamamoto2, Patrick Hanssens3, Guus Beute3, Takuya Kawabe2, Takao Koiso2, Michael Söderman4, Keith Lim5, Charles L Rosen6, Tseng Tsai Yeo7.   

Abstract

OBJECTIVE: To assess if modern management of extracranial malignant diseases has prolonged the survival times for patients with more than 2 brain metastases (BM).
METHODS: Data from 2385 patients treated with Gamma Knife surgery (GKS) for ≥3 BM between 1982 and 2011 were retrospectively analyzed. The patients were divided into 6 groups based on the treatment year and the median and 10% survival times were compared with the median and mean treatment dates in each group.
RESULTS: The later the treatment date, the longer the median as well as the 10% survival times. The relation between the median treatment date and both the 10% and median survival times could be accurately expressed by a linear as well as an exponential curve fit. The median and 10% survival times increased by around 80% and 150%, respectively, between 1990 and 2010.
CONCLUSIONS: Both the median and 10% survival times have increased in recent years among patients with more than 2 BM treated with GKS. Both linear and exponential regressions accurately expressed the increase in both median and 10% survival times during the years 1990-2010. Findings from other published data support the observation of longer survival times among patients treated more recently, independent of the patients being treated with GKS or with whole-brain radiation therapy with or without radiosurgery. Thus, earlier findings of short survival times for patients with multiple BM are no longer valid, at least not for patients deemed suitable for radiosurgery. Aggressive management is thus warranted for these patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multiple brain metastases; Radiation therapy; Survival time

Mesh:

Year:  2016        PMID: 27154179     DOI: 10.1016/j.wneu.2016.04.089

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  2 in total

1.  Impact of PTV margin reduction (2 mm to 0 mm) on pseudoprogression in stereotactic radiotherapy of solitary brain metastases.

Authors:  Justine Badloe; Mirjam Mast; Anna Petoukhova; Jan-Huib Franssen; Elyas Ghariq; Noëlle van der Voort van Zijp; Ruud Wiggenraad
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-03-03

Review 2.  Brain metastases: increasingly precision medicine-a narrative review.

Authors:  Michael Jerome McKay
Journal:  Ann Transl Med       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.